Sandler Alan B
Department of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-6307, USA.
Semin Oncol. 2005 Dec;32(6 Suppl 10):S16-22. doi: 10.1053/j.seminoncol.2005.10.006.
The prognosis for the majority of patients with lung cancer remains poor, and treatment strategies including newer generation chemotherapeutics have not improved survival. New approaches are required to further improve patient outcome and survival. Recently, key molecules involved in signal transduction pathways that contribute to tumor growth have been identified as therapeutic targets, particularly molecules involved in cellular proliferation and angiogenesis. Novel therapeutics that specifically target angiogenesis have shown promise as single agents and in combination with standard chemotherapy. The results of recent studies validate the use of this class of targeted therapeutics as an important new treatment modality in cancer therapy. This review will focus on a discussion of antiangiogenic therapeutic monoclonal antibodies in development for the treatment of non-small cell lung cancer.
大多数肺癌患者的预后仍然很差，包括新一代化疗药物在内的治疗策略并未提高生存率。需要新的方法来进一步改善患者的治疗效果和生存率。最近，参与肿瘤生长信号转导途径的关键分子已被确定为治疗靶点，特别是参与细胞增殖和血管生成的分子。特异性靶向血管生成的新型治疗药物已显示出作为单一药物以及与标准化疗联合使用的前景。最近的研究结果证实了这类靶向治疗药物作为癌症治疗中一种重要的新治疗方式的应用。本综述将重点讨论正在开发的用于治疗非小细胞肺癌的抗血管生成治疗性单克隆抗体。
